+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID05710679

Evaluating Circulating DNA to Predict Residual Disease After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Led by Centre Jean Perrin · Updated on 2026-09-11

63

Participants Needed

4

Research Sites

117 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of circulating DNA detection to predict residual disease in patients with locally advanced head and neck squamous cell carcinomas HNSCCs treated with potentiated radiotherapy. Locally advanced HNSCCs have high rates of locoregional failure, and current imaging methods like PET-CT have limitations in accurately detecting residual disease due to false positives caused by inflammation. This study aims to assess whether circulating tumor DNA ctDNA, including circulating HPV16 viral DNA cvDNA, can provide more reliable information about treatment response and residual disease. Participants will have blood samples collected twice once before treatment and again three months after radiochemotherapy if imaging shows an incomplete response. The study focuses on patients undergoing potentiated radiotherapy combined with chemotherapy regimens including Docetaxel, Platinum, and 5-Fluorouracil. This single-arm, open-label, multicenter study monitors ctDNA and compares it with PET-CT results to evaluate its value in detecting residual disease and predicting patient outcomes. During the study, participants will undergo PET-CT scans and blood sampling to measure ctDNA levels. Researchers will track the rate of incomplete cervical lymph node response on PET-CT and the presence of circulating DNA three months after treatment. Additional assessments include evaluating concordance between tumor and circulating DNA profiles, reproducibility of imaging interpretations, and long-term monitoring of clinical and pathological features. The study extends up to 66 months to observe outcomes and includes regular clinical follow-up to assess the prognostic value of ctDNA and HPV-related markers.

CONDITIONS

Brief Title

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Research Team

A

Angeline GINZAC COUVÉ, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here